When divided into early (Barcelona Clinic Liver Cancer (BCLC) 0/A, Figure 3H) and late (BCLC B/C/D, Figure 3I) stage disease, survival differences according to ULPB1 levels in both groups showed raised hazard ratios for death, suggesting ULBP1 may be prognostic in both early and late disease, although p values were non-significant owing to a lack of statistical power (median survival 1077 vs. 535 days, p = 0.15, HR = 2.9 in early stage, 399 vs. 198 days, p = 0.096, HR = 1.8 in late stage). This evidence concerns the gene ULBP1 and liver cancer.